Cargando…
Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report
Cholangiocarcinoma (CCA) is a malignant tumor with poor prognosis and high recurrence rate. There is no standard treatment for advanced CCA beyond first-line chemotherapy, which provides only limited benefits. In this study, we report a case of a postoperative recurrence ECC patient harboring a brea...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506765/ https://www.ncbi.nlm.nih.gov/pubmed/34734039 http://dx.doi.org/10.21037/atm-21-3681 |
_version_ | 1784581755666169856 |
---|---|
author | Li, Wenxin Ma, Zuohong Fu, Xibo Hao, Zhiqiang Shang, Hai Shi, Junping Lei, Mengping Xu, Mian Ning, Shili Hua, Xiangdong |
author_facet | Li, Wenxin Ma, Zuohong Fu, Xibo Hao, Zhiqiang Shang, Hai Shi, Junping Lei, Mengping Xu, Mian Ning, Shili Hua, Xiangdong |
author_sort | Li, Wenxin |
collection | PubMed |
description | Cholangiocarcinoma (CCA) is a malignant tumor with poor prognosis and high recurrence rate. There is no standard treatment for advanced CCA beyond first-line chemotherapy, which provides only limited benefits. In this study, we report a case of a postoperative recurrence ECC patient harboring a breast cancer 2 (BRCA2)-inactivating rearrangement mutation that had an obvious reaction to olaparib therapy. The patient was a 68-year-old man with postoperative recurrence of extrahepatic CCA (ECC) who declined systemic chemotherapy. In August 2015, abdominal computed tomography (CT) of the patient revealed intrahepatic bile duct dilatation, obstruction at the hepatic hilar region proximal to the common hepatic duct, and splenomegaly, and radical surgical resection was performed. Postoperative histopathology diagnosis was ECC without metastases. In February 2017, abdominal CT revealed local recurrence, and the patient refused chemotherapy. BRCA2 rearrangement were detected by next-generation sequencing. Oral administration of olaparib was initiated. The patient achieved stable disease 1 month later, progression-free survival for >10 months without any significant adverse reactions, and an overall survival (OS) of 27 months. This is the first report demonstrating the clinical benefits of olaparib in a BRCA2 rearrangement-harboring patient with ECC. This observation would help determine the best treatment option for advanced ECC patients. |
format | Online Article Text |
id | pubmed-8506765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-85067652021-11-02 Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report Li, Wenxin Ma, Zuohong Fu, Xibo Hao, Zhiqiang Shang, Hai Shi, Junping Lei, Mengping Xu, Mian Ning, Shili Hua, Xiangdong Ann Transl Med Case Report Cholangiocarcinoma (CCA) is a malignant tumor with poor prognosis and high recurrence rate. There is no standard treatment for advanced CCA beyond first-line chemotherapy, which provides only limited benefits. In this study, we report a case of a postoperative recurrence ECC patient harboring a breast cancer 2 (BRCA2)-inactivating rearrangement mutation that had an obvious reaction to olaparib therapy. The patient was a 68-year-old man with postoperative recurrence of extrahepatic CCA (ECC) who declined systemic chemotherapy. In August 2015, abdominal computed tomography (CT) of the patient revealed intrahepatic bile duct dilatation, obstruction at the hepatic hilar region proximal to the common hepatic duct, and splenomegaly, and radical surgical resection was performed. Postoperative histopathology diagnosis was ECC without metastases. In February 2017, abdominal CT revealed local recurrence, and the patient refused chemotherapy. BRCA2 rearrangement were detected by next-generation sequencing. Oral administration of olaparib was initiated. The patient achieved stable disease 1 month later, progression-free survival for >10 months without any significant adverse reactions, and an overall survival (OS) of 27 months. This is the first report demonstrating the clinical benefits of olaparib in a BRCA2 rearrangement-harboring patient with ECC. This observation would help determine the best treatment option for advanced ECC patients. AME Publishing Company 2021-09 /pmc/articles/PMC8506765/ /pubmed/34734039 http://dx.doi.org/10.21037/atm-21-3681 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Case Report Li, Wenxin Ma, Zuohong Fu, Xibo Hao, Zhiqiang Shang, Hai Shi, Junping Lei, Mengping Xu, Mian Ning, Shili Hua, Xiangdong Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report |
title | Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report |
title_full | Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report |
title_fullStr | Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report |
title_full_unstemmed | Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report |
title_short | Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report |
title_sort | olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a brca2-inactivating mutation: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506765/ https://www.ncbi.nlm.nih.gov/pubmed/34734039 http://dx.doi.org/10.21037/atm-21-3681 |
work_keys_str_mv | AT liwenxin olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport AT mazuohong olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport AT fuxibo olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport AT haozhiqiang olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport AT shanghai olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport AT shijunping olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport AT leimengping olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport AT xumian olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport AT ningshili olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport AT huaxiangdong olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport |